GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (FRA:SG7) » Definitions » Cyclically Adjusted PS Ratio

Sage Therapeutics (FRA:SG7) Cyclically Adjusted PS Ratio : 2.26 (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-06-05), Sage Therapeutics's current share price is €10.175. Sage Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €4.51. Sage Therapeutics's Cyclically Adjusted PS Ratio for today is 2.26.

The historical rank and industry rank for Sage Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:SG7' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.18   Med: 5.86   Max: 10.97
Current: 2.18

During the past years, Sage Therapeutics's highest Cyclically Adjusted PS Ratio was 10.97. The lowest was 2.18. And the median was 5.86.

FRA:SG7's Cyclically Adjusted PS Ratio is ranked better than
71.23% of 504 companies
in the Biotechnology industry
Industry Median: 5.505 vs FRA:SG7: 2.18

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sage Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.121. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €4.51 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sage Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sage Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Cyclically Adjusted PS Ratio Chart

Sage Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 6.79 4.32

Sage Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.73 9.01 4.10 4.32 3.82

Competitive Comparison of Sage Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Sage Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sage Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's Cyclically Adjusted PS Ratio falls into.



Sage Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sage Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=10.175/4.51
=2.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sage Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Sage Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.121/131.7762*131.7762
=0.121

Current CPI (Mar. 2024) = 131.7762.

Sage Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 1.655 106.317 2.051
201809 0.000 106.507 0.000
201812 0.005 105.998 0.006
201903 0.008 107.251 0.010
201906 0.015 108.070 0.018
201909 0.063 108.329 0.077
201912 0.034 108.420 0.041
202003 0.040 108.902 0.048
202006 0.019 108.767 0.023
202009 0.027 109.815 0.032
202012 16.224 109.897 19.454
202103 0.023 111.754 0.027
202106 0.023 114.631 0.026
202109 0.021 115.734 0.024
202112 0.025 117.630 0.028
202203 0.024 121.301 0.026
202206 0.024 125.017 0.025
202209 0.030 125.227 0.032
202212 0.045 125.222 0.047
202303 0.052 127.348 0.054
202306 0.038 128.729 0.039
202309 0.042 129.860 0.043
202312 1.192 129.419 1.214
202403 0.121 131.776 0.121

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sage Therapeutics  (FRA:SG7) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sage Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sage Therapeutics (FRA:SG7) Business Description

Traded in Other Exchanges
Address
215 First Street, Cambridge, MA, USA, 02142
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Sage Therapeutics (FRA:SG7) Headlines

No Headlines